Literature DB >> 7606952

Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma.

T Osaki1, T Mitsudomi, T Oyama, R Nakanishi, K Yasumoto.   

Abstract

Serum levels of c-erbB-2 protein were measured by an enzyme immunoassay in 64 patients with lung adenocarcinoma. Immunohistochemical staining was performed in 40 of these tumors. The mean serum concentration was 16.5 +/- 8.5 U/mL (range: 3.4 to 49.0) in patients with lung adenocarcinoma, whereas it was 14.0 +/- 3.7 U/mL (range: 6.9 to 20.9) in 15 controls (1 U/mL = 0.61 ng/mL). Elevated concentrations (> or = 22.0 U/mL, control mean + 2 SD) were observed in 17/64 lung adenocarcinoma patients (26.6%), as compared with none of the control subjects (p < 0.05). Patients with stage IIIB or T4 disease had increased serum levels. The serum concentration was decreased significantly by surgical tumor ablation. Tissue overexpression was obtained in 17/40 cases (42.5%), and serum levels in patients with tissue overexpression were higher than in patients without overexpression. Serum c-erbB-2 protein may be a useful indicator of tumor burden in patients with lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606952     DOI: 10.1378/chest.108.1.157

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  9 in total

1.  Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications.

Authors:  T Osaki; T Oyama; M Inoue; C D Gu; M Kodate; M Aikawa; T So; M Mizukami; T Mitsudomi; K Yasumoto
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2001-09

2.  Heliox in the treatment of chronic obstructive pulmonary disease.

Authors:  R Andrews; M Lynch
Journal:  Emerg Med J       Date:  2004-11       Impact factor: 2.740

3.  Evidence-based prevention (EBP): A review of cytochrome P450 expression in the bronchial epithelium and new approach to lung cancer prevention.

Authors:  Tsunehiro Oyama; Toyohi Isse; Tomoe Murakami; Rie Suzuki-Narai; Masanori Ogawa; Tetsunosuke Yamaguchi; Tsuyoshi Kinaga; Yasunori Yashima; Shinichi Ozaki; Yong-Dae Kim; Heon Kim; Toshihiro Kawamoto
Journal:  Environ Health Prev Med       Date:  2006-05       Impact factor: 3.674

4.  Pilot study of the clinical significance of serum and urinary her-2/neu protein in bladder cancer patients.

Authors:  Taek Sang Kim; Hyun Yul Rhew; Hyun Yong Hwang
Journal:  Korean J Urol       Date:  2011-12-20

5.  A novel differential diagnostic model for multiple primary lung cancer: Differentially-expressed gene analysis of multiple primary lung cancer and intrapulmonary metastasis.

Authors:  Dali Chen; Longyong Mei; Yubin Zhou; Cheng Shen; Huan Xu; Zhongxi Niu; Guowei Che
Journal:  Oncol Lett       Date:  2015-01-15       Impact factor: 2.967

6.  Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer.

Authors:  W Jacot; J-L Pujol; J-M Boher; P-J Lamy
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

Review 7.  The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature.

Authors:  A-P Meert; B Martin; M Paesmans; T Berghmans; C Mascaux; J-M Verdebout; P Delmotte; J-J Lafitte; J-P Sculier
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

8.  Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma.

Authors:  Abby L Cosentino-Boehm; Jacqueline M Lafky; Tammy M Greenwood; Kimberly D Kimbler; Marites C Buenafe; Yuxia Wang; Adam J Branscum; Ping Yang; Nita J Maihle; Andre T Baron
Journal:  Diagnostics (Basel)       Date:  2013-01-14

9.  Clinical significance of serum and urinary HER2/neu protein levels in primary non-muscle invasive bladder cancer.

Authors:  Ozgur Arikan; Asýf Yýldýrým; Banu Ýsbilen; Cengiz Canakci; Gokhan Atýs; Cenk Gurbuz; Bulent Erol; Ferruh Kemal Ýsman; Seyma Ozkanli; Turhan Caskurlu
Journal:  Int Braz J Urol       Date:  2015 Nov-Dec       Impact factor: 1.541

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.